BRPI0417043A - composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição - Google Patents
composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composiçãoInfo
- Publication number
- BRPI0417043A BRPI0417043A BRPI0417043-1A BRPI0417043A BRPI0417043A BR PI0417043 A BRPI0417043 A BR PI0417043A BR PI0417043 A BRPI0417043 A BR PI0417043A BR PI0417043 A BRPI0417043 A BR PI0417043A
- Authority
- BR
- Brazil
- Prior art keywords
- solid dosage
- dosage form
- composition
- pharmaceutical composition
- lercanidipine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA, FORMA DE DOSAGEM SóLIDA, MéTODO DE MANUFATURA DE FORMA DE DOSAGEM SóLIDA, E, USO DA COMPOSIçãO". Uma composição farmacêutica de liberação controlada compreendendo lercanidipina dissolvida ou dispersada em um veículo sólido na temperatura ambiente, formando assim uma dispersão sólida, alcança a liberação retardada de lercanidipina durante um período de tempo prolongado, efeito de alimentação reduzida e biodisponibilidade aumentada comparada com os produtos contendo lercanidipina comercialmente disponíveis.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301778 | 2003-12-01 | ||
DKPA200400249 | 2004-02-18 | ||
US55378704P | 2004-03-16 | 2004-03-16 | |
PCT/DK2004/000836 WO2005053689A2 (en) | 2003-12-01 | 2004-12-01 | Pharmaceutical compositions comprising lercanidipine |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0417043A true BRPI0417043A (pt) | 2007-02-06 |
Family
ID=34657505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0417043-1A BRPI0417043A (pt) | 2003-12-01 | 2004-12-01 | composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070105912A1 (pt) |
EP (1) | EP1694305B1 (pt) |
JP (1) | JP2007512265A (pt) |
KR (1) | KR20060125824A (pt) |
AU (1) | AU2004294674B2 (pt) |
BR (1) | BRPI0417043A (pt) |
CA (1) | CA2547657A1 (pt) |
DE (1) | DE04801160T1 (pt) |
EA (1) | EA013426B1 (pt) |
ES (1) | ES2281313T3 (pt) |
IL (1) | IL175973A (pt) |
MX (1) | MXPA06006118A (pt) |
NO (1) | NO340114B1 (pt) |
WO (1) | WO2005053689A2 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101111245A (zh) * | 2005-01-27 | 2008-01-23 | 阿雷姆贝克有限公司 | 左乙拉西坦延长释放制剂 |
AR053023A1 (es) * | 2005-02-25 | 2007-04-18 | Recordati Ireland Ltd | Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen |
WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
MX2009002166A (es) * | 2006-08-31 | 2009-03-12 | Eurand Inc | Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos. |
US20080175872A1 (en) * | 2006-09-28 | 2008-07-24 | Osmotica Corp. | Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid |
GB0709541D0 (en) * | 2007-05-17 | 2007-06-27 | Jagotec Ag | Pharmaceutical excipient |
AU2007356942B2 (en) * | 2007-07-23 | 2011-12-15 | Pharmathen S.A. | Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
AR072477A1 (es) * | 2008-07-11 | 2010-09-01 | Solvay Pharm Bv | Formulacion farmaceutica de eprosartan. uso. |
US20100209348A1 (en) * | 2009-02-18 | 2010-08-19 | Arondo Pharma, Inc. | Methods for determining liposome bioequivalence |
EP2598136A4 (en) * | 2010-07-27 | 2015-03-25 | Teva Pharma | DISPERSIONS OF RASAGILINE CITRATE |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
UY33772A (es) * | 2010-12-09 | 2012-07-31 | Lg Life Sciences Ltd | Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma. |
EP2654729B1 (en) * | 2010-12-24 | 2016-05-04 | KRKA, d.d., Novo mesto | Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid |
BR112015015858B1 (pt) * | 2013-01-14 | 2023-02-28 | Infirst Healthcare Limited | Uso de uma composição farmacêutica de solução sólida no tratamento de uma inflamação crônica |
EP3218006A4 (en) * | 2014-11-11 | 2018-08-15 | Verdure Sciences | Stable solid lipid particle composition for improved bioavailability of lipophilic compounds for age-related diseases |
JP7378393B2 (ja) * | 2017-11-10 | 2023-11-13 | オースティンピーエックス リミテッド ライアビリティ カンパニー | 改善された薬物製剤 |
JP6983139B2 (ja) * | 2017-11-27 | 2021-12-17 | 信越化学工業株式会社 | 固形製剤用組成物並びに固形製剤及びその製造方法 |
US20210145036A1 (en) * | 2018-04-17 | 2021-05-20 | Poviva Tea, Llc | Lipophilic active agent infused compositions with reduced food effect |
CN115837012A (zh) * | 2021-01-18 | 2023-03-24 | 广州一品红制药有限公司 | 一种氨氯地平干混悬剂及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20011726A1 (it) * | 2001-08-06 | 2003-02-06 | Recordati Ind Chimica E Farma | Forme polimorfe della lercanidipina cloridrato |
US20030180355A1 (en) * | 2001-10-16 | 2003-09-25 | Amedeo Leonardi | Combination therapy for hypertension |
-
2004
- 2004-12-01 CA CA002547657A patent/CA2547657A1/en not_active Abandoned
- 2004-12-01 US US10/581,128 patent/US20070105912A1/en not_active Abandoned
- 2004-12-01 JP JP2006540183A patent/JP2007512265A/ja active Pending
- 2004-12-01 ES ES04801160T patent/ES2281313T3/es active Active
- 2004-12-01 AU AU2004294674A patent/AU2004294674B2/en not_active Ceased
- 2004-12-01 BR BRPI0417043-1A patent/BRPI0417043A/pt not_active IP Right Cessation
- 2004-12-01 MX MXPA06006118A patent/MXPA06006118A/es not_active Application Discontinuation
- 2004-12-01 EA EA200601075A patent/EA013426B1/ru not_active IP Right Cessation
- 2004-12-01 DE DE04801160T patent/DE04801160T1/de active Pending
- 2004-12-01 WO PCT/DK2004/000836 patent/WO2005053689A2/en active Application Filing
- 2004-12-01 KR KR1020067013018A patent/KR20060125824A/ko not_active Application Discontinuation
- 2004-12-01 EP EP04801160.5A patent/EP1694305B1/en active Active
-
2006
- 2006-05-28 IL IL175973A patent/IL175973A/en active IP Right Grant
- 2006-06-29 NO NO20063036A patent/NO340114B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2281313T3 (es) | 2020-07-24 |
CA2547657A1 (en) | 2005-06-16 |
MXPA06006118A (es) | 2006-08-11 |
JP2007512265A (ja) | 2007-05-17 |
KR20060125824A (ko) | 2006-12-06 |
AU2004294674B2 (en) | 2009-02-26 |
EA200601075A1 (ru) | 2006-12-29 |
EP1694305A2 (en) | 2006-08-30 |
EA013426B1 (ru) | 2010-04-30 |
AU2004294674A1 (en) | 2005-06-16 |
ES2281313T1 (es) | 2007-10-01 |
IL175973A0 (en) | 2006-10-05 |
US20070105912A1 (en) | 2007-05-10 |
WO2005053689A3 (en) | 2006-04-27 |
NO340114B1 (no) | 2017-03-13 |
EP1694305B1 (en) | 2019-10-16 |
DE04801160T1 (de) | 2007-08-09 |
IL175973A (en) | 2016-03-31 |
NO20063036L (no) | 2006-09-01 |
WO2005053689A2 (en) | 2005-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0417043A (pt) | composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição | |
ATE386508T1 (de) | Feste orale dosierungsform enthaltend einen resorptionsverstärker | |
AU2002218167A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
BRPI0513455A (pt) | formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada | |
IL168266A (en) | Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments | |
HUP0203451A2 (hu) | Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra | |
JP2004523498A5 (pt) | ||
JP2004529078A5 (pt) | ||
CY1110558T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
SG170087A1 (en) | Pharmaceutical compositions | |
EE05287B1 (et) | Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
BR0013157A (pt) | Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna | |
AU2003246810A1 (en) | Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives | |
IS6002A (is) | Pýrazólkarboxýlsýruafleiður, framleiðsla þeirra, lyfjasamsetningar sem innihalda þær | |
WO2005000232A3 (en) | Six membered amino-amide derivatives as angiogenesis inhibitors | |
NO20062824L (no) | 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme | |
CY1105028T1 (el) | Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες | |
BR0015256A (pt) | Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano | |
TNSN07337A1 (en) | Pharmaceutical composition comprising an indolylmaleimide derivative | |
CY1110913T1 (el) | Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα | |
NO20045385L (no) | Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff | |
DE69923336D1 (de) | Oral anzuwendende buprenorphinhaltige arzneimittel | |
BR9916575A (pt) | Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa | |
CY1105019T1 (el) | Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες | |
BR0313220A (pt) | Pelìcula de revestimento para comprimidos e cápsulas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S) |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |